Cutter Capital Management
Latest statistics and disclosures from Cutter Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are REGN, JNJ, RPRX, ABBV, RARE, and represent 40.02% of Cutter Capital Management's stock portfolio.
- Added to shares of these 10 stocks: JNJ (+$21M), ABBV (+$18M), TEVA (+$13M), REGN (+$12M), AMGN (+$9.9M), NAMS (+$8.7M), MRNA (+$8.2M), JANX (+$6.4M), AKRO (+$6.4M), TARS (+$6.2M).
- Started 11 new stock positions in TARS, NAMS, JANX, JNJ, AKRO, AMGN, MRNA, NMRA, TEVA, CNTA. ABBV.
- Reduced shares in these 10 stocks: GILD (-$30M), BMY (-$30M), , LEGN (-$16M), LLY (-$15M), HRMY (-$15M), , SWTX (-$12M), AXSM (-$9.5M), IOVA (-$8.2M).
- Sold out of its positions in A, ACLX, RNA, AXSM, BCRX, BMY, ELVN, GILD, HRMY, NTLA. IONS, IOVA, LEGN, LLY, SWTX, AVDL, JAZZ.
- Cutter Capital Management was a net seller of stock by $-79M.
- Cutter Capital Management has $244M in assets under management (AUM), dropping by -27.97%.
- Central Index Key (CIK): 0001983313
Tip: Access up to 7 years of quarterly data
Positions held by Cutter Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Cutter Capital Management
Cutter Capital Management holds 21 positions in its portfolio as reported in the December 2024 quarterly 13F filing
Company (Ticker) |
Portfolio Weight |
Valued At |
Change in Shares |
Share Count |
Share Price |
|
|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals (REGN) | 9.2 | $22M | +117% | 32k | 712.33 |
|
| Johnson & Johnson (JNJ) | 8.4 | $21M | NEW | 142k | 144.62 |
|
| Royalty Pharma Shs Class A (RPRX) | 8.0 | $20M | +15% | 765k | 25.51 |
|
| Abbvie (ABBV) | 7.4 | $18M | NEW | 102k | 177.70 |
|
| Ultragenyx Pharmaceutical (RARE) | 7.0 | $17M | +41% | 407k | 42.07 |
|
| Bridgebio Pharma (BBIO) | 6.3 | $15M | +41% | 560k | 27.44 |
|
| Sarepta Therapeutics (SRPT) | 6.2 | $15M | +48% | 124k | 121.59 |
|
| Insmed Com Par $.01 (INSM) | 6.0 | $15M | -2% | 211k | 69.04 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 5.3 | $13M | NEW | 585k | 22.04 |
|
| Miragen Therapeutics (VRDN) | 4.9 | $12M | +21% | 629k | 19.17 |
|
| Amgen (AMGN) | 4.1 | $9.9M | NEW | 38k | 260.64 |
|
| Agios Pharmaceuticals (AGIO) | 4.1 | $9.9M | +61% | 302k | 32.86 |
|
| Vera Therapeutics Cl A (VERA) | 3.7 | $9.0M | +23% | 213k | 42.29 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 3.6 | $8.7M | NEW | 337k | 25.70 |
|
| Moderna (MRNA) | 3.4 | $8.2M | NEW | 198k | 41.58 |
|
| Perrigo SHS (PRGO) | 3.1 | $7.6M | -47% | 295k | 25.71 |
|
| Janux Therapeutics (JANX) | 2.6 | $6.4M | NEW | 120k | 53.54 |
|
| Akero Therapeutics (AKRO) | 2.6 | $6.4M | NEW | 230k | 27.82 |
|
| Tarsus Pharmaceuticals (TARS) | 2.6 | $6.2M | NEW | 113k | 55.37 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.0 | $2.5M | NEW | 147k | 16.75 |
|
| Neumora Therapeutics (NMRA) | 0.7 | $1.6M | NEW | 150k | 10.60 |
|
Past Filings by Cutter Capital Management
SEC 13F filings are viewable for Cutter Capital Management going back to 2023
- Cutter Capital Management 2024 Q4 filed Feb. 14, 2025
- Cutter Capital Management 2024 Q3 filed Nov. 14, 2024
- Cutter Capital Management 2024 Q2 filed Aug. 14, 2024
- Cutter Capital Management 2024 Q1 amended filed Aug. 6, 2024
- Cutter Capital Management 2024 Q1 filed May 15, 2024
- Cutter Capital Management 2023 Q4 filed Feb. 14, 2024